Cargando…

Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse

INTRODUCTION: C-X-C motif chemokine 10 (CXCL10) is a chemokine that plays a critical role in the infiltration of T cells in autoimmune diseases and is reported to be expressed in muscle tissue of polymyositis. To determine the therapeutic efficacy of CXCL10 blockade, we investigated the role of CXCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jinhyun, Choi, Ji Yong, Park, Sung-Hye, Yang, Seung Hee, Park, Ji Ah, Shin, Kichul, Lee, Eun Young, Kawachi, Hiroshi, Kohsaka, Hitoshi, Song, Yeong Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095607/
https://www.ncbi.nlm.nih.gov/pubmed/24939012
http://dx.doi.org/10.1186/ar4583
_version_ 1782326061429686272
author Kim, Jinhyun
Choi, Ji Yong
Park, Sung-Hye
Yang, Seung Hee
Park, Ji Ah
Shin, Kichul
Lee, Eun Young
Kawachi, Hiroshi
Kohsaka, Hitoshi
Song, Yeong Wook
author_facet Kim, Jinhyun
Choi, Ji Yong
Park, Sung-Hye
Yang, Seung Hee
Park, Ji Ah
Shin, Kichul
Lee, Eun Young
Kawachi, Hiroshi
Kohsaka, Hitoshi
Song, Yeong Wook
author_sort Kim, Jinhyun
collection PubMed
description INTRODUCTION: C-X-C motif chemokine 10 (CXCL10) is a chemokine that plays a critical role in the infiltration of T cells in autoimmune diseases and is reported to be expressed in muscle tissue of polymyositis. To determine the therapeutic efficacy of CXCL10 blockade, we investigated the role of CXCL10 and the effect of anti-CXCL10 antibody treatment in C protein-induced myositis (CIM), an animal model of polymyositis. METHODS: CIM was induced with human skeletal muscle C protein fragment in female C57BL/6 mice. Immunohistochemistry of CXCL10 and C-X-C motif chemokine receptor 3 (CXCR3) and measurement of serum CXCL10 were performed. Cell surface markers and interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) in CIM lymph node cells was investigated by flow cytometry. Mice with CIM were treated with anti-CXCL10 antibody or control antibody (anti-RVG1) and the inflammation in muscle tissue was assessed. RESULTS: Immunohistochemistry showed increased expression of CXCL10 and CXCR3 in the inflammatory lesions of muscle in CIM. Especially, CD8+ T cells invading myofiber expressed CXCR3. Serum level of CXCL10 was increased in CIM compared to the level in normal mice (normal mouse, 14.3 ± 5.3 pg/ml vs. CIM, 368.5 ± 135.6 pg/ml, P < 0.001). CXCR3 positivity in CD8+ T cells was increased compared to that of CD4+ T cells in the lymph node cells of CIM (CXCR3+ among CD8+ T cell, 65.9 ± 2.1% vs. CXCR3+ among CD4+ T cell, 23.5 ± 4.7%, P <0.001). Moreover, IFN-γ+ cells were increased among CXCR3+CD8+ T cells compared to CXCR3–CD8+ T cells (CXCR3+CD8+ T cell, 28.0 ± 4.2% vs. CXCR3-CD8+ T cell, 9.5 ± 1.5%, P = 0.016). Migration of lymph node cells was increased in response to CXCL10 (chemotactic index was 1.91 ± 0.45). CIM mice treated with anti-CXCL10 antibody showed a lower inflammation score in muscles than those with anti-RVG1 (median, anti-CXCL10 treatment group, 0.625 vs. anti-RVG1 treatment group, 1.25, P = 0.007). CONCLUSIONS: CXCL10/CXCR3 expression was increased in the inflammation of CIM model and its blockade suppressed inflammation in muscle.
format Online
Article
Text
id pubmed-4095607
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40956072014-07-14 Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse Kim, Jinhyun Choi, Ji Yong Park, Sung-Hye Yang, Seung Hee Park, Ji Ah Shin, Kichul Lee, Eun Young Kawachi, Hiroshi Kohsaka, Hitoshi Song, Yeong Wook Arthritis Res Ther Research Article INTRODUCTION: C-X-C motif chemokine 10 (CXCL10) is a chemokine that plays a critical role in the infiltration of T cells in autoimmune diseases and is reported to be expressed in muscle tissue of polymyositis. To determine the therapeutic efficacy of CXCL10 blockade, we investigated the role of CXCL10 and the effect of anti-CXCL10 antibody treatment in C protein-induced myositis (CIM), an animal model of polymyositis. METHODS: CIM was induced with human skeletal muscle C protein fragment in female C57BL/6 mice. Immunohistochemistry of CXCL10 and C-X-C motif chemokine receptor 3 (CXCR3) and measurement of serum CXCL10 were performed. Cell surface markers and interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) in CIM lymph node cells was investigated by flow cytometry. Mice with CIM were treated with anti-CXCL10 antibody or control antibody (anti-RVG1) and the inflammation in muscle tissue was assessed. RESULTS: Immunohistochemistry showed increased expression of CXCL10 and CXCR3 in the inflammatory lesions of muscle in CIM. Especially, CD8+ T cells invading myofiber expressed CXCR3. Serum level of CXCL10 was increased in CIM compared to the level in normal mice (normal mouse, 14.3 ± 5.3 pg/ml vs. CIM, 368.5 ± 135.6 pg/ml, P < 0.001). CXCR3 positivity in CD8+ T cells was increased compared to that of CD4+ T cells in the lymph node cells of CIM (CXCR3+ among CD8+ T cell, 65.9 ± 2.1% vs. CXCR3+ among CD4+ T cell, 23.5 ± 4.7%, P <0.001). Moreover, IFN-γ+ cells were increased among CXCR3+CD8+ T cells compared to CXCR3–CD8+ T cells (CXCR3+CD8+ T cell, 28.0 ± 4.2% vs. CXCR3-CD8+ T cell, 9.5 ± 1.5%, P = 0.016). Migration of lymph node cells was increased in response to CXCL10 (chemotactic index was 1.91 ± 0.45). CIM mice treated with anti-CXCL10 antibody showed a lower inflammation score in muscles than those with anti-RVG1 (median, anti-CXCL10 treatment group, 0.625 vs. anti-RVG1 treatment group, 1.25, P = 0.007). CONCLUSIONS: CXCL10/CXCR3 expression was increased in the inflammation of CIM model and its blockade suppressed inflammation in muscle. BioMed Central 2014 2014-06-17 /pmc/articles/PMC4095607/ /pubmed/24939012 http://dx.doi.org/10.1186/ar4583 Text en Copyright © 2014 Kim et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kim, Jinhyun
Choi, Ji Yong
Park, Sung-Hye
Yang, Seung Hee
Park, Ji Ah
Shin, Kichul
Lee, Eun Young
Kawachi, Hiroshi
Kohsaka, Hitoshi
Song, Yeong Wook
Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title_full Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title_fullStr Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title_full_unstemmed Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title_short Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse
title_sort therapeutic effect of anti-c-x-c motif chemokine 10 (cxcl10) antibody on c protein-induced myositis mouse
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095607/
https://www.ncbi.nlm.nih.gov/pubmed/24939012
http://dx.doi.org/10.1186/ar4583
work_keys_str_mv AT kimjinhyun therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT choijiyong therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT parksunghye therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT yangseunghee therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT parkjiah therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT shinkichul therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT leeeunyoung therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT kawachihiroshi therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT kohsakahitoshi therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse
AT songyeongwook therapeuticeffectofanticxcmotifchemokine10cxcl10antibodyoncproteininducedmyositismouse